Heron Therapeutics | HRTX - Assets


Heron Therapeutics reported $252.26M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
ALKERMES USD 4.39B 135.05M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amarin USD 624.36M 21.4M Jun/2026
ANI Pharmaceuticals USD 1.49B 72.14M Jun/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
Eisai JPY 1.56T 108.98B Jun/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Insmed USD 2.1B 26.7M Jun/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.24B 35.44M Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Veracyte USD 1.49B 49.97M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026